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Background
The relationship between ACPA and the clinical outcome
of rheumatoid arthritis (RA) under treatment has been
evaluated in clinical trials with conflicting results. Thus,
the response to treatment was influenced by ACPA in the
BeSt study. However, radiological damage progression was
more likely among ACPA-positive patients. Conversely,
ACPA-negative patients achieved less remissions in the
IMPROVED study. Because of these, we evaluated the
clinical response (CR) of patients with RA receiving treat-
ment according to ACPA titers.
Patients and methods
All patients seen at our Unit who fulfilled the following
criteria were included in this retrospective study: 1) Diag-
nosis of RA by a rheumatologist meeting the 1987 criteria
for RA; 2) Available determinations of ACPA; 3) Treat-
ment for AR (whether or not biological therapy) with a
minimum follow up of 6 months. The outcome variable
was CR defined as reaching DAS28 <1.6. Predictors of CR
were evaluated using logistic regression.
Results
71 patients were included, 79% of them women. CR was
observed in 19 (27%) patients during the first 12 months
of follow-up. Baseline median (IQR) ACPA levels were
306 (7-500) for individuals without CR and 76 (7-153) for
those with CR (p=0.022). 29 (56%) patients without CR vs.
5 (26%) with CR showed ACPA levels ≥200 (p=0.028).
ACPA levels decreased significantly among patients with
CR (p=0.019), but they did not change in those without
CR (p=0.330). Factors independently associated with CR
were: recent onset RA [adjusted odds ratio (AOR) 0.19;
95% confidence interval (95%CI) 0.41-0.90; p=0.036], base-
line ACPA levels ≥200 [AOR 6.48; 95%CI 1.12-37.3;
p=0.037], baseline CRP levels [per unit increase; AOR
1.06; 95%CI 1.001-1.12; p=0.048], baseline DAS28 [per
unit increase; AOR 3.04; 95%CI 1.3-7.4; p=0.014].
Conclusions
ACPA levels can predict CR of patients with RA receiving
treatment in real life conditions. Individuals with high
ACPA levels may benefit from a more aggressive treat-
ment approach. Titers of ACPA may be useful to monitor
the clinical activity of RA.
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